Synairgen (LON:SNG) Shares Up 33.3% – Here’s What Happened

Synairgen plc (LON:SNG) shot up 33.3% on Monday . The company traded as high as GBX 3 ($0.04) and last traded at GBX 3 ($0.04). 205,983 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 332,641 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Stock Down 10.2 %

The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The firm has a market capitalization of £4.07 million, a P/E ratio of -67.33 and a beta of -2.23. The stock has a fifty day moving average price of GBX 3.98 and a two-hundred day moving average price of GBX 4.12.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).